Tixagevimab and cilgavimab: Can we see more recommendations for monoclonal antibodies beyond COVID-19 vaccination

Basit Öğe Kaydı
dc.authoridAnmar Al-Taie / 0000-0002-2183-6830en_US
dc.authorscopusidAnmar Al-Taie / 57221579036
dc.authorwosidAnmar Al-Taie / I-8549-2019en_US
dc.contributor.authorAl-Taie, Anmar
dc.date.accessioned2022-06-15T13:46:30Z
dc.date.available2022-06-15T13:46:30Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Ana Bilim Dalıen_US
dc.description.abstractNearly three years after its detection, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome CoV-2, is still a life-threatening global pandemic health disease that contributed to a high progression and mortality. This imposes the scientific researching efforts to hold intense interest directed to explore for the development and optimizing different interventions to COVID-19 infection. This commentary summarizes the potential clinical benefits for the recently authorized immunotherapy combination of tixagevimab and cilgavimab monoclonoal antibodies for the prevention and treatment of COVID-19.en_US
dc.identifier.citationAl-Taie A. Tixagevimab and Cilgavimab: Can We See More Recommendations for Monoclonal Antibodies beyond COVID-19 Vaccination. Disaster Med Public Health Prep. 2022 Jun 8:1-5. doi: 10.1017/dmp.2022.150. Epub ahead of print. PMID: 35672931.en_US
dc.identifier.doi10.1017/dmp.2022.150en_US
dc.identifier.issn1935-7893en_US
dc.identifier.pmid35672931en_US
dc.identifier.scopus2-s2.0-85131923111en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttp://doi.org/10.1017/dmp.2022.150
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2903
dc.identifier.wosWOS:000828891500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAl-Taie, Anmar
dc.language.isoenen_US
dc.publisherCambridge University Pressen_US
dc.relation.ispartofDisaster Medicine and Public Health Preperadnessen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCilgavimaben_US
dc.subjectCOVID-19en_US
dc.subjectMonoclonal Antibodiesen_US
dc.subjectTixagevimaben_US
dc.subjectVaccinationen_US
dc.titleTixagevimab and cilgavimab: Can we see more recommendations for monoclonal antibodies beyond COVID-19 vaccinationen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
tixagevimab-and-cilgavimab-can-we-see-more-recommendations-for-monoclonal-antibodies-beyond-covid-19-vaccination.pdf
Boyut:
302.48 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Eczacılık Temel Bilimleri Bölümü Makale Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu